drugset / Trial / NCT01900704

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4

NCT01900704

Phase 3 Completed 810 enrolled Serenity Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia

Timeline

Start
2013-08
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 750 ng Intranasal
Subject Desmopressin Peptide 1500 ng Intranasal

Indications